Clinical trial · Observational
Small and Steatotic Hepatocellular Carcinoma
Small and Steatotic Hepatocellular Carcinoma : a Distinctive Radiological Variant With Improved Outcome After Percutenous Ablation
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Percutaneous thermoablation in an effective local curative treatment in patients with cirrhosis and HCC smaller than 3 cm in diameter (BCLC 0-A). Around 30% of HCC patients referred for percutaneous ablation were regarded as non-feasible because of a difficult-at risk location or undetectable nodules. We used percutaneous thermoablation to treat HCC on high risk locations (subcapsular or liver dome) with or without lipiodol marked (for undetectable HCC). No clinical study has been published so far to compare percutaneous thermoablation of HCC on liver dome CT guided with artificial pneumothorax and lipiodol marked, and percutaneous thermoablation of HCC guided by ultrasonography (non subcapsular, distent form diaphragm). This retrospective study evaluate the overall survival, the local tumor progression or distant liver progression after percutaneous ablation for HCC and determine prognostic factors.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| HCC | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Thermal ablations
- timeFrame
- 1 day
- description
- Evaluation of thermal ablations (radiofrequency and microwave ablation)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion criteria: * HCC according to histological examination or Barcelona criteria * BCLC0 or A * Measurable targets according to mRECIST v1.1 * Child A or B7 cirrhosis * HCC \< 4 cm, \< 3 nodules, Age ≥ 18 years * No extrahepatic metastasis, no vascular invasion * Performance status 0 or 1 * Thrombocytes ≥ 50 000/mm3, TP \> 50% Exclusion criteria: * Follow-up \< 1month * Lobar/main portal venous thrombus * Abundant ascites * Antecedent of bilio-digestive anastomosis or endoscopic sphincterotomy * Combined treatment with embolization or chemo-embolization
References
Publications (0)
Data not yet available